DEALS

Zhong Lun Advises on CARsgen Therapeutics’ IPO in Hong Kong

Release time：2021-06-18 Voice Announcements

On June 18, 2021, CARsgen Therapeutics Holdings Limited (2171.HK) announced the closing of its initial public offering on the Main Board of the Stock Exchange of Hong Kong Limited, raising the net proceeds of approximately HK$2.94 billion prior to the exercise of the over-allotment option. Goldman Sachs and UBS acted as joint sponsors for the offering.

CARsgen Therapeutics focuses on innovative CAR-T cell therapies for the treatment of hematological malignancies and solid tumors. It has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR-T cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors and reducing treatment costs. By the end of May 2021, CARsgen Therapeutics had obtained seven IND clearances for CAR-T therapies in China, the United States and Canada, ranking the first among all CAR-T companies in China, according to Frost & Sullivan, the industry consultant of the issuer.

Zhong Lun Law Firm acted as the PRC legal advisor to the joint sponsors in this offering. The legal team from Zhong Lun was led by Anthony Zhao, Catherine Chen, William Jia and Shaun Gao, and included Roy Zheng, Lindsay Zhang, etc.

Previous：Zhong Lun Law Firm Represented THE COLOR RUN before the Supreme People’s Court and Won Favorable Judgment in A Trademark Invalidation Case Next：Zhong Lun represents OCBC on an Onshore and Offshore Financing Project

Print articles from Zhong Lun

Insights >

Publiciations >

Monthly Highlights >

Articles

Deals

Zhong Lun Assists Multiple Humanoid Robot and Intelligent Equipment Science and Technology Companies and Investors in Completing Tens of Millions Yuan Financing and Investment

Zhong Lun Advises on CR Beverage’s IPO in Hong Kong

Events

Awards

Zhong Lun Advises on CARsgen Therapeutics’ IPO in Hong Kong